ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Grossman Leads Neuro-Oncology Society; NYU Recruits Radiation Oncology Director.

January 14, 2000

Panel Waffles On One Vs. Three Year Intervals For Pap Test, Agrees On when They Should Start

August 1, 1980

Protocols Approved By NCI During January 2004

February 27, 2004

Hellman, Suit Awarded ASTRO’s Gold Medals

October 26, 1990

ABMT Trials Unlikely To show Clean Benefit for Breast Cancer; Data Release Debated

March 12, 1999

Letter To the Editor; Closed Meetings Create Aura of Suspicion

August 12, 1994